Login / Signup

Is polypharmacy associated with mortality in the very old: Findings from the Newcastle 85+ Study.

Laurie E DaviesAndrew KingstonAdam ToddBarbara Hanratty
Published in: British journal of clinical pharmacology (2022)
Polypharmacy is common in the very old (≥85 years), where little is known about its association with mortality. We aimed to investigate the association between polypharmacy and all-cause mortality in the very old, over an 11-year time period. Data were drawn from the Newcastle 85+ Study (741), a cohort of people who were born in 1921 and turned 85 in 2006. Survival analysis was performed using Cox proportional hazards models with time-varying covariates, wherein polypharmacy was operationalised continuously. Each additional medication prescribed was associated with a 3% increased risk of mortality (hazard ratio: 1.03, 95% confidence interval: 1.00-1.06). Amongst the very old, the risks and benefits of each additional medication prescribed should be carefully considered.
Keyphrases
  • adverse drug
  • healthcare
  • risk factors
  • electronic health record
  • emergency department
  • big data
  • risk assessment
  • climate change
  • disease virus
  • artificial intelligence
  • gestational age
  • human health
  • free survival